

Galileo Biotech Innovation Fund

Investing in the future of biotechnology

Market

The fund offers focused access to companies in the field of genome editing. Representing the next step in the evolution of medical technology, genome editing holds the potential to cure a variety of rare diseases but also offers a novel approach to more common conditions with established treatments. Further applications range from livestock to crop science.

Approach

We choose a thematic approach since we believe that estimating the success probabilities of individual companies in genome editing is heavily error prone and can lead to missed opportunities and cluster risks.

We aim to hold between 25-40 companies, providing us with exposure while offering enough diversification to accommodate for larger volatility associated with early-stage investments. Further, we believe this is the sweet spot to capitalize on the theme while staying focused.

We exclude companies where we see funding, balance sheet or governance issues.

There is no focus on a specific medical field, e.g. oncology, hematology etc. Furthermore, no limitations on upper or lower market capitalizations are in place.

Spotlight


HIV: Immune deficiency caused by the HI virus attacking T-cells on the basis of the active CCR5 gene. First studies show that altering the gene or shutting it down completely lead to positive results. Clinical studies are ongoing.

Organ donation: The shortage of organ donations lead to research using pig organs; so far with limited success. Genome editing, however, has shown first results in preventing auto-immune reactions and shutting down over 62 viral genes prevalent in pig organs which have the potential to infect human cells.

Consequently, there is a large growth opportunity not only in the rare disease space but also the potential to capture market share in already treatable diseases. While there is ample runway to expand revenue and profits, innovation leaders with successful products may become takeover targets for large pharma and biotech companies.

Genome editing

We view genome editing as an umbrella term encompassing gene therapy, cell therapy and gene editing. All approaches entail some form of altering genetic information through a variety of methods (e.g. TALENs, CRISPR, meganuclease etc.) in order to enable cells to perform a desired function.




Transfer-messenger RNA bound to a ribosome with elongation factor G and a transfer RNA.

Leukemia: A form of cancer which attacks the lymphatic system. Cell therapy has shown promising results by altering T-cells and curing the patient.

Duchenne Muscular Dystrophy: The genetic disorder leads to progressive muscle degeneration and weakness due to a mutation in the Dystrophin gene and therefore a lack of the protein Dystrophin. The illness often forces patients into the wheelchair at a young age. Untreated, life expectancy is rarely above 30. First studies with mice showed that the gene can be reactivated.

Manager



Cyrill Plüss

Lead Portfolio Manager

Cyrill is engaged in portfolio management and the investment process at Bellecapital. His experience includes work in an M&A boutique with focus on specialty chemicals company transactions and in the finance department of Syngenta Europe. He last worked as Equity Research Analyst at Kepler Capital Markets in Zurich. At Kepler, he mainly covered Swiss technology stocks. He graduated from the University of St. Gallen (HSG) with a major in Finance.

Disclaimer

This document is for marketing purposes. Please read the current sales prospectus and the KID before entering in any transaction. The only basis for the purchase of a fund are the Key Information Document (KID), the current Sales Prospectus with the Management Regulations or the articles of incorporation, the most recently published and audited Annual Report and the most recently published unaudited Semi-Annual Report, which can be obtained free of charge in German language from IPConcept (Luxemburg) S.A. (société anonyme), 4, rue Thomas Edison L-1445, Strassen, Luxemburg (see also https://www.ipconcept.com/ipc/en/funds_overview.html). Risks can be found in the Sales Prospectus. The Sales Prospectus and the KIDs must be made available to the investor prior to purchase. The tax treatment depends on the individual circumstances of each investor. This marketing communication is for information purposes only and does not constitute an offer to buy or sell fund units. In particular, the recipient is advised to check the information with regard to its compatibility with his or her own personal circumstances, legal, regulatory, tax and other consequences, if necessary with the assistance of an advisor. Please refer to the current sales prospectus for information on opportunities and risks. No assurance can be given that the investment objectives will be achieved. This marketing communication is addressed exclusively to interested parties in the countries in which the aforementioned fund is authorised for public distribution. The Fund was established under Luxembourg law and is authorised for distribution in Luxembourg, Germany, Liechtenstein and Switzerland. The Fund may not be publicly offered for sale in the United States of America ("USA") or for the benefit of US persons. The Management Company may decide to discontinue the arrangements it has made for the distribution of the units of its collective investment undertakings in accordance with Article 93a of Directive 2009/65/EC. Further information on investor rights in English <https://www.ipconcept.com/ipc/en/investor-information.html> and German language <https://www.ipconcept.com/ipc/de/anlegerinformation.html> can be found on the Management Company's website (www.ipconcept.com). For investors in Switzerland: The representative is IPConcept (Schweiz) AG, Bellerivestrasse 36, P.O. Box, CH-8008 Zurich and the paying agent is DZ PRIVATBANK (Schweiz) AG, Bellerivestrasse 36, P.O. Box, CH-8008 Zurich. The Prospectus, the Key Investor Information Document and the Annual and Semi-Annual Reports may be obtained free of charge from the Representative in Switzerland. Past performance, simulations or forecasts are no reliable indicator of future performance. The gross performance according to the BVI method does not take into account the costs charged on the issue and redemption of units (issue and redemption premium) and fees incurred during the holding period (e.g. transaction costs). The investor may incur securities account costs and other costs (e.g. custody or safekeeping costs), which reduce the performance. It should be noted that the value of the acquired units may fluctuate due to fluctuations in the investments in the fund and the listing of the securities. The fund exhibits increased volatility due to the composition of its portfolio or the portfolio management techniques used, i.e. the unit price may be subject to considerable upward and downward fluctuations even within short periods of time. Furthermore, in the case of foreign currencies, the return may rise or fall as a result of currency fluctuations.